16.10 USD
▼-0.19-1.17%
盘后 16.12 +0.12%
2026-09-15
市值
$1.72B
市盈率
—
EPS
-1.10
股息率
—
52 周区间
4.96 – 18.89
成交量
2.43M
Beta
2.32
目标价
15.44
52W 低 4.9652W 高 18.89
价格走势
公司简介
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample....